Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.
Malignant Melanoma Stage IV|Malignant Melanoma Stage IIIc
DRUG: Trametinib
Best Overall Response, Participants will be followed for the duration of hospital stay, an expected average of 18 months., Up to 18 months|Adverse Event Rates, Percentage of patients developing an Adverse Event through follow-up, Participants will be followed for the duration of hospital stay, an expected average of 18 months.
Overall Survival, Number of patients alive at the end of the follow-up period and median time between start of treatment and death., Participants will be followed for the duration of hospital stay, an expected average of 18 months.|Resectability of tumor, Proportion of patients whom tumor was resectable, Participants will be followed for the duration of hospital stay, an expected average of 18 months.|Adherence to treatment, Proportion of patients who comply with treatment as prescribed, Participants will be followed for the duration of hospital stay, an expected average of 18 months.
The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.